1 CD4 1 Treg have a crucial role in self-tolerance. The ability to generate similar populations against alloantigens offers the possibility of preventing transplant rejection without indefinite global immunosuppression. Exposure of mice to donor alloantigens combined with anti-CD4 antibody induces operational tolerance to cardiac allografts, and generates Treg that prevent skin and islet allograft rejection in adoptive transfer models. If protocols that generate Treg in vivo are to be developed in the clinical setting it will be important to know the origin of the Treg population and the mechanisms responsible for their generation. In this study, we demonstrate that graftprotective Treg arise in vivo both from naturally occurring FOXP3 Thus, adaptive tolerance induction shapes the immune response to alloantigen by converting potential effector cells into graft-protective Treg and by expanding alloreactive naturally occurring Treg. In relation to clinical tolerance induction, the data indicate that while the generation of alloreactive Treg may be critical for long-term allograft survival without chronic immunosuppression, successful protocols will also require strategies that target potential effector cells.
Introduction
Current therapy for patients undergoing transplantation relies upon indefinite non-specific immunosuppression to prevent rejection. Although modern immunosuppressive regimens have dramatically improved early transplant outcomes [1] , there has been less impact on the rate of late graft loss [2] . Furthermore, chronic immunosuppression exposes transplant recipients to drug toxicity and an increased risk of malignancy [3] and infection [4] . A growing understanding of the intrinsic immunological mechanisms that control autoimmunity has led to the concept that targeted immune-manipulation with agents such as anti-CD3 [5] or anti-CD52 antibodies [6, 7] may promote regulation of donordirected immune responses, thus leading to improved graft outcomes while preserving protective immunity.
Naturally occurring CD4 1 Treg that develop in the thymus under the control of the transcription factor foxp3 [8] [9] [10] have a critical role in peripheral immune homeostasis and lack of Treg, due to congenital deficiency of foxp3 [11, 12] or selective depletion of foxp3-expressing cells, [13, 14] results in fatal autoimmune disease. In addition to controlling auto-reactive cells, Treg have also been shown to suppress immune responses to foreign antigens in the context of pregnancy [15] , malignancy [16] , infection [17] and transplantation [18] . In several experimental models, Treg are essential for the induction and maintenance of transplantation tolerance [19] [20] [21] [22] [23] and the fact that regulation invariably depends on TCR ligation provides the possibility of using specific antigens to induce regulatory function in defined situations. We have shown that pre-treatment of naïve mice with a DST (donor-specific transfusion) combined with anti-CD4 mAb generates CD25
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1 T cells that prevent rejection of skin allografts by a defined effector population in lymphopenic adoptive transfer recipients [21, 24] . Importantly, this tolerance induction protocol also leads to indefinite cardiac allograft survival in immunologically intact recipients [25] . Successful translation of tolerance induction for potential therapeutic use will depend on an understanding of how alloantigen-reactive Treg are generated. In this study we provide evidence that graft-protective Treg can arise in vivo both by expansion of endogenous, naturally occurring FOXP3 
Results
Tolerance induction with anti-CD41DST is dependent on CD25 1 Treg CBA (H2 k ) mice pre-treated with DST and non-depleting anti-CD4 mAb (YTS177.9) on days 28 and 27 accept donor cardiac allografts on day 0 without further immunotherapy [25] . To test the hypothesis that heart allograft survival in immunocompetent primary recipients is dependent on induced CD25
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1 Treg, CBA mice were pre-treated with anti-CD41H2 b DST on days 28 and 27, 7anti-CD25 mAb (PC61) on day 14 and transplanted with H2 b cardiac allografts on day 0 (Fig. 1A) . Administration of anti-CD25 mAb results in 490% depletion of CD25 Tolerised mice accepted donor grafts indefinitely (n 5 6, MST (median survival time)4100 days, Fig. 1C ) but in contrast, mice that also received depleting anti-CD25 mAb rejected their grafts acutely (n 5 6, MST 25 days) confirming that CD25
1 Treg have a non-redundant role in allograft acceptance in this model, a finding supported by recent work demonstrating that ligation of glucocorticoid-induced TNFR-related protein (GITR) at the time of transplantation also prevents graft acceptance [20] . 
1 cells from WT mice in order to assess the importance of non-regulatory cell conversion in allograft tolerance.
Although B6 (H2 b ) FOXP3 GFP -reporter were available to us, we deliberately sought a strategy that would allow us to isolate CD4 1 T cells devoid of nTreg from CBA (H2 k ) mice to allow direct comparisons to be made with the results of our previous study [24] . To identify surrogate markers that might allow flow-purification of FOXP3 negative cells, un-stimulated CBA CD4
1 T cells were stained for FOXP3 and markers associated with Treg phenotype and function, including CD127, CD25, GITR, CTLA-4, CD62L, CD45RB and CD103. The markers that allowed the most consistent discrimination between FOXP3 1 and FOXP3 À cells were GITR, CD45RB and CD25
( Fig. 3B) . The data were then re-analysed using pairs of markers to calculate potential yields and purities from FACS sorting. The highest predicted purity and yield of CD4 signal (Fig. 4D) on day À1 and either no pre-treatment or anti-CD4 mAbs alone (Fig. 5A ).
As shown in Fig. 5B , adoptive transfer control and anti-CD4 control mice rejected their skin allografts acutely (MST 19 days, n 5 6 and 19 days n 5 4, respectively). In contrast, the majority of mice in the tolerance induction group accepted their grafts long term (MST4100 days, n 5 8) with no signs of graft necrosis (Fig. 5C) . Thus, Treg with the capacity to prevent skin allograft rejection can be converted from FOXP3 À precursors, implying that naturally occurring Treg are not required for tolerance induction in all situations.
To test the hypothesis that tolerance induction induces FOXP3 expression in non-regulatory cells, further cohorts of CBA.rag 
FOXP3
À cells as above, with or without tolerance induction (Fig. 6A) . On day 0, spleens were harvested and FOXP3 expression analysed by FACS. FOXP3 1 cells were readily detected in both tolerised mice and controls (Fig. 6B) , and unexpectedly there was no significant difference in the absolute number of FOXP3 1 T cells between the two groups ( Fig. 6C) , indicating that homeostatic proliferation of FOXP3 À cells is sufficient to drive FOXP3 expression, consistent with other recent reports [34, 35] . Critically, however, only Treg generated following tolerance induction were capable of preventing graft rejection (Fig. 5) . These data highlight an important functional distinction between Treg generated in the presence or absence of tolerogenic therapy, and again show the limitations of phenotypic analysis for inferring Treg function, particularly in lymphopenic recipients.
To look for evidence of conversion in immunocompetent recipients where homeostatic proliferation should not be a confounding factor, 3 Â 10 6 FACS sorted CD45.2
GFP -reporter mice were adoptively transferred into congenic CD45.1 1 H2 b recipients, and these mice then received the tolerising anti-CD4/DST protocol (Fig. 7A) . The purity of the sorted input GFP À population was 499% (Fig. 7B) . Control mice received anti-CD4 mAb alone, DST alone or adoptive transfer only. On day 0, spleens were harvested and analysed by FACS. Transferred cells were readily identified as indicated by the analysis gate (Fig. 7C ). As shown in Fig. 7D , the absolute number of CD45. 
Tolerance induction inhibits Th1 effector cell priming and in vitro cytotoxicity
Naïve CD4 1 T cells exhibit plasticity following activation and can differentiate into diverse effector populations that in unmodified transplant recipients lead to allograft rejection. We have obtained evidence in two different systems that tolerance induction can result in the emergence of regulatory cells from non-regulatory precursors, but hitherto we have neglected the possible impact of tolerance induction on potential effector cells within the T-cell compartment. Previous work in human renal transplantation has shown a positive correlation between increased frequencies of donor-reactive IFN-gsecreting T cells and a higher incidence of acute rejection, chronic allograft nephropathy and reduced 1-year allograft function [36] [37] [38] . Therefore, IFN-g ELISpot analysis was used to examine the impact of tolerance induction on alloreactive effector T-cell responses. CBA mice were tolerised with the anti-CD41DST protocol and controls received anti-CD4 mAb alone, DST alone or no treatment (Fig. 8A ). Spleens were harvested on day 0 and CD4 , respectively), indicating that in addition to promoting the development of Treg, a further key effect of tolerance induction in this protocol is an inhibition of alloreactive Th1 priming.
T-cell effector function was also evaluated in this system using an in vitro cytotoxicity assay. To ask whether there is a difference in the ability of T cells from tolerant mice to kill donor strain targets, total T cells from un-manipulated or tolerised mice were purified by negative selection and re-stimulated with irradiated donor (H2 b ) splenocytes ( 
Discussion
Several experimental approaches for the induction of donor-specific transplantation tolerance have been validated in rodents and in many of these models. CD25 [39] . Similarly, it has recently been shown that when transferred to T cell-deficient hosts, FOXP3 1 T cells can accumulate in Peyer's patches of the gut and promote germinal centre formation and B-cell activation. Significantly, the majority of T cells participating in these interactions lose FOXP3 expression [40] . Although the cues that drive functional plasticity have not been fully elucidated, it seems quite likely that inflammation and the presence or absence of TGF-b play an important role [41] . This seems to be particularly the case with respect to Th17 and induced (adaptive) Treg where fate-switching seems to be dependent on the local availability of TGF-b [42] . In this regard, it is interesting to note that the anti-CD4/DST protocol delivers alloantigen via the A B C intravenous route and thus challenges the immune system in the absence of overt inflammation. Thus, one simple possibility is that in the absence of inflammation, plasticity can result in a non-Treg to Treg conversion (Fig. 5 and 7) , while in the presence of inflammation, the opposite occurs. A simple distinction in outcome based on the presence or absence of inflammation would have clear physiological benefits in the context of wider immunity by maintaining peripheral regulation of responses to self but also allowing the rapid elaboration of protective immunity following infection where the presence of pathogens is invariably accompanied by pro-inflammatory stimuli [43] . In this regard it is interesting to note that in an analogous mouse tolerance induction model, while pre-treatment with an anti-CD154/DST protocol leads to long-term cardiac allograft survival, the addition of TLR9 ligation by co-delivery of exogenous CpG results in acute rejection [44] . Thus, the inflammatory context in which alloantigen is first encountered appears to have a significant impact on the eventual immunological outcome.
An additional aspect raised by the current study is that although much of the evidence for T-cell plasticity has been obtained by adoptive transfer of defined populations into lymphopenic or T-cell-depleted hosts, the data in Fig. 7 demonstrate that non-Treg to Treg plasticity can be detected in immunocompetent hosts. This appears to be an important observation with respect to transplantation because it implies that it may be possible to convert naïve alloreactive CD4
1 T cells into graftprotective Treg in clinical transplant recipients without the need for large-scale T-cell depletion. Several publications support the observation that uncommitted non-Treg can undergo peripheral conversion into cells that are phenotypically and functionally indistinguishable from naturally occurring Treg [31, 32, [45] [46] [47] . However, a recent study from 
CD4
1 T cells rather than total T cells, implying that input Treg are necessary for tolerance induction. The predominant pathway of allorecognition through which graft-protective Treg are generated following tolerance induction is unclear but one possible explanation for the contradiction between the data presented in Fig. 5 (MHC mismatch) and those reported by Nagahama et al. is that conversion of nonTreg precursors during tolerance induction occurs predominantly within the direct rather than the indirect alloreactive T-cell pool.
Although there is evidence that CD8 1 T cells can be regulated by CD4 1 adaptive Treg [49] , it is likely that to achieve operational tolerance in the wider setting, additional strategies will be required to control CD8 responses, particularly those of CD8 memory cells [50] .
In this study we demonstrate that total T cells from tolerised mice kill donor-strain cells less efficiently than cells from un-manipulated mice, raising the possibility that in addition to generating CD4 1 Treg, tolerance induction in this system leads to the functional deletion of alloreactive cytotoxic CD8 1 cells. Indeed, a previous study of tolerance induction using anti-CD154 mAb1DST provided clear evidence for such a deletion [51] . Further support for this possibility is provided by the finding that co-stimulation blockade was significantly less effective at prolonging allograft survival in mice where T-cell resistance to activation-induced cell death was induced by BCL-XL expression, implying that in some situations, deletion of effector T cells can be an important component of tolerance induction [52] . Combining tolerogenic therapy with T-cell depletion has been suggested previously as a method of improving the ratio of graftdestructive and graft-protective T cells [52, 53] but large-scale T-cell depletion places patients at increased risk of infection and posttransplant lymphoproliferative disease [54] . Our data demonstrate that alloantigen-dependent tolerance induction has multiple effects on the recipient immune system, and suggest that in the quest for clinical transplantation tolerance, attention should be focused on developing protocols that not only generate graft-protective Treg but also target potential effector cells. Given the low abundance of nTreg, the possibility of generating graft protective Treg in vivo from the much larger pool of alloreactive non-regulatory T cells is very attractive for the induction of tolerance in the clinic. .1) mice are as described previously [55] .
Materials and methods
Antibodies
The hybridomas YTS169 (anti-CD8) and YTS177.9 (anti-CD4) were kindly provided by Prof. H. Waldmann (Sir William Dunn School of Pathology, Oxford). The hybridomas TIB120 (anti-MHC class II) and PC61 (anti-CD25) were from the ATCC. Conjugated antibodies were from eBioscience (DTA-1, anti-GITR; PC61.5, anti-CD25; H57-597, anti-TCR-b; FJK-16s, anti-FOXP3; GK1.5, anti-CD4) or BD Pharmingen (AF6-88.5, anti-K b ).
Tolerance induction protocol
Mice received 200 mg of anti-CD4 mAb (YTS177.9) i.v. on days 28 and 27 and a DST (250 mL of whole donor-strain blood) i.v. on day 27.
Skin transplantation
Full-thickness tail skin allografts were transplanted onto recipient graft beds. Rejection was defined as complete graft necrosis. Survival was compared using the Log-rank test.
Heart transplantation
Heterotopic cardiac transplants were performed essentially as described previously [56] . Rejection was defined as lack of palpable cardiac contraction and confirmed by laparotomy.
Cell purification
T cells were purified by magnetic separation as described previously [21] or by flow cytometry (BD FACSAria).
IFN-c ELISpot assay
Ninety-six-well MultiScreen plates (Millipore) were coated with capture mAb (AN18, Mabtech). Responder and stimulator cells were incubated for 14 h followed by washing. Detection mAb (biotinylated R4-6A2, Mabtech) was added, incubated for 2 h at room temperature followed by washing. StreptavidinAlkaline phosphatase (Mabtech,) was added for 1 h. Plates were washed and developing substrate (Mabtech) was added. Spots were enumerated with an AID ViruSpot plate reader and ViruSpot 3.3 software (Autoimmun Diagnostika GmbH, Germany).
In vitro cytotoxicity assay 
